CN102695717B - T细胞受体 - Google Patents

T细胞受体 Download PDF

Info

Publication number
CN102695717B
CN102695717B CN201080053971.2A CN201080053971A CN102695717B CN 102695717 B CN102695717 B CN 102695717B CN 201080053971 A CN201080053971 A CN 201080053971A CN 102695717 B CN102695717 B CN 102695717B
Authority
CN
China
Prior art keywords
tcr
cells
ebv
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080053971.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102695717A (zh
Inventor
H.斯陶斯
S-A.薛
M.托普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN102695717A publication Critical patent/CN102695717A/zh
Application granted granted Critical
Publication of CN102695717B publication Critical patent/CN102695717B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201080053971.2A 2009-09-29 2010-09-28 T细胞受体 Expired - Fee Related CN102695717B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0917090.3A GB0917090D0 (en) 2009-09-29 2009-09-29 T-cell receptor
GB0917090.3 2009-09-29
PCT/GB2010/001821 WO2011039508A2 (en) 2009-09-29 2010-09-28 T-cell receptor

Publications (2)

Publication Number Publication Date
CN102695717A CN102695717A (zh) 2012-09-26
CN102695717B true CN102695717B (zh) 2016-08-10

Family

ID=41350560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080053971.2A Expired - Fee Related CN102695717B (zh) 2009-09-29 2010-09-28 T细胞受体

Country Status (10)

Country Link
US (1) US8889141B2 (cg-RX-API-DMAC7.html)
EP (1) EP2483294B1 (cg-RX-API-DMAC7.html)
JP (2) JP6180114B2 (cg-RX-API-DMAC7.html)
KR (1) KR101760277B1 (cg-RX-API-DMAC7.html)
CN (1) CN102695717B (cg-RX-API-DMAC7.html)
AU (1) AU2010302477B2 (cg-RX-API-DMAC7.html)
ES (1) ES2584541T3 (cg-RX-API-DMAC7.html)
GB (1) GB0917090D0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN02993A (cg-RX-API-DMAC7.html)
WO (1) WO2011039508A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108218976A (zh) * 2016-12-09 2018-06-29 广东香雪精准医疗技术有限公司 衍生自lmp1的肿瘤抗原短肽

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
RS61455B1 (sr) 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
EP3495483A1 (en) 2012-09-12 2019-06-12 International Institute of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
PT3149031T (pt) * 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
IL281396B (en) * 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
KR101794304B1 (ko) 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN109963860A (zh) * 2016-09-19 2019-07-02 拜耳作物科学股份公司 吡唑并[1,5-a]吡啶衍生物及其作为农药的用途
WO2019031938A2 (ko) 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
SG11202101671PA (en) 2018-11-27 2021-03-30 Univ Duke Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
WO2020133050A1 (zh) * 2018-12-27 2020-07-02 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
EP3786178A1 (en) * 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
EP3940075A1 (en) * 2020-07-17 2022-01-19 Istituto Nazionale Di Genetica Molecolare-INGM Inhibitors of line1 and uses thereof
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182531B (zh) * 2007-11-09 2010-06-02 暨南大学 Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Retroviral Transduction of a T Cell Receptor Specific for an Epstein–Barr Virus-Encoded Peptide;Rimas J.et al.,;《Clinical immunology》;20010228;第98卷(第2期);摘要，正文221页左栏倒数第一段-226页左栏第一段，introduction和disscission部分） *
Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells;HART D P et al.,;《GENE THERAPY》;20080430;第15卷(第8期);625-631 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108218976A (zh) * 2016-12-09 2018-06-29 广东香雪精准医疗技术有限公司 衍生自lmp1的肿瘤抗原短肽
CN108218976B (zh) * 2016-12-09 2021-11-05 香雪生命科学技术（广东）有限公司 衍生自lmp1的肿瘤抗原短肽

Also Published As

Publication number Publication date
US20120244132A1 (en) 2012-09-27
EP2483294B1 (en) 2016-07-13
GB0917090D0 (en) 2009-11-11
JP2016047064A (ja) 2016-04-07
IN2012DN02993A (cg-RX-API-DMAC7.html) 2015-07-31
AU2010302477B2 (en) 2017-01-19
US8889141B2 (en) 2014-11-18
KR101760277B1 (ko) 2017-07-21
WO2011039508A3 (en) 2011-06-30
EP2483294A2 (en) 2012-08-08
WO2011039508A2 (en) 2011-04-07
JP2013505734A (ja) 2013-02-21
AU2010302477A1 (en) 2012-04-19
CN102695717A (zh) 2012-09-26
JP6180114B2 (ja) 2017-08-16
ES2584541T3 (es) 2016-09-28
KR20120074291A (ko) 2012-07-05

Similar Documents

Publication Publication Date Title
US8889141B2 (en) T-cell receptor
CN102656188B (zh) 能够识别来自巨细胞病毒的抗原的t细胞受体
US10004801B2 (en) HBV epitope reactive exogenous T cell receptor (TCR) and uses thereof
CN108395479B (zh) 一种有关kras基因突变的t细胞受体
EP3615565A1 (en) Tcr and peptides
AU2017205637A1 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
BR112014024893B1 (pt) Sequência de ácido nucleico isolada ou purificada que codifica um receptor de antígeno quimérico (car) e seu uso, cars isolados ou purificados, vetores, métodos para destruir células cancerígenas e polinucleotídeo
CN102272153A (zh) 高亲和力t细胞受体及其应用
WO2016095783A1 (zh) 识别eb病毒短肽的t细胞受体
CN110272482A (zh) 识别prame抗原短肽的t细胞受体
US10251936B2 (en) EBV antigen specific T-cell receptor and use thereof
CN118541388A (zh) 识别p53中r175h突变的t细胞受体及其应用
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
JP2023518446A (ja) ループスを処置するための組成物及び方法
WO2025110187A1 (ja) Ｈｌａ－ａ０２拘束性グリピカン３由来ペプチド特異的ｔｃｒ
WO2025176853A1 (en) Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor
CN117736298A (zh) T细胞抗原受体及其制备方法和应用
CN110272481A (zh) 识别mage1抗原短肽的t细胞受体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160810

Termination date: 20190928

CF01 Termination of patent right due to non-payment of annual fee